EPIDERMAL GROWTH FACTOR RECEPTOR L858R MUTANT

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 14:41:34 GMT 2023` Edited by `admin` on `Sat Dec 16 14:41:34 GMT 2023`
Protein Type	RECEPTOR
Protein Sub Type	GROWTH FACTOR RECEPTOR
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	4P6Y9ZK0WL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EPIDERMAL GROWTH FACTOR RECEPTOR L858R MUTANT

Common Name

English

EGFR L858R

Common Name

English

EGFR L858R MUTATION

Common Name

English

Code System Code Type Description

FDA UNII

4P6Y9ZK0WL

Created by admin on Sat Dec 16 14:41:35 GMT 2023 , Edited by admin on Sat Dec 16 14:41:35 GMT 2023

PRIMARY

UNIPROT

P00533

Created by admin on Sat Dec 16 14:41:35 GMT 2023 , Edited by admin on Sat Dec 16 14:41:35 GMT 2023

PRIMARY

From	To
1_7	1_34
1_133	1_163
1_166	1_175
1_170	1_183
1_191	1_199
1_195	1_207
1_208	1_216
1_212	1_224
1_227	1_236
1_240	1_267
1_271	1_283
1_287	1_302
1_305	1_309
1_313	1_338
1_446	1_475
1_482	1_491
1_486	1_499
1_502	1_511
1_515	1_531
1_534	1_547
1_538	1_555
1_558	1_567
1_571	1_593
1_596	1_604
1_600	1_612

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_104
N	1_151
N	1_172
N	1_328
N	1_337
N	1_389
N	1_420
N	1_504
N	1_544
N	1_579
N	1_599

Related Record Type Details


					HYW8DB273J

BRIGATINIB

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					41OXH4FE7B

AV-412 FREE BASE

INHIBITOR -> TARGET

Interaction Type:

IRREVERSIBLE INHIBITOR

Qualification:

IC50

Amount:


					4A2Y23XK11

LAZERTINIB

INHIBITOR -> TARGET


					A49A7A5YN4

Firmonertinib

INHIBITOR -> TARGET

Comments:

Potent irreversible inhibitor of EGFR harbouring resistance (T790M) or activating (L858R and exon 19 deletions) mutations [6]. The half maximal inhibitory concentration (IC50) of furmonertinib against these mutant EGFRs is ≈ 1 nmol/L, which is lower than its IC50 against wild-type EGFR.

Qualification:

IC50

Amount: